Poelman E, et al. - Physicians designed this study to assess whether immunomodulation at the start of enzyme replacement therapy induced immune tolerance to recombinant human acid alpha-glucosidase (rhGAA) in patients with classic infantile Pompe disease. Only during B cell depletion, immunomodulation prevented the formation of rhGAA antibodies but failed to induce immune tolerance in 2/3 patients.